Sildenafil citrate was a failed hypertension drug. Had it not been for Territ & Ellis two clinical researchers, Pfizer would have never further developed it to the success we all know it has become today for erectile dysfunction.
Squalamine could be found to eradicate shorts permanently.
Shorting high interest calls has become a sure bet to make money in GERN. Happened last month with $5 calls exactly the same as it happened this month with $5 calls on the eve of a potential news event. Both turned out to be positive events and yet the SP languishes below $5. This is a great retail trap that issuing hedge funds are making a bundle on. The game is transparent and any trader or brokerage can depend on it. See the options interest for next month. $4 puts has the greatest interest as do the $5 calls. SP will be held within that range favouring the one with the least($5puts). As to March, $5 & $8 calls seem to have the highest interest. GERN could spike up there by then but will settle back down to today's range for options expiration.
These trading levels ensured by your friendly hedge fund's profit motive till a major catalyst triggers a game change for higher priced options interest.
"One stock that might be an intriguing choice for investors right now is Geron Corporation (GERN). This is because this security in the Biotechnology industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Biotechnology industry space as it currently has a Zacks Industry Rank of 64 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Geron Corporation is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term."
"2014 Top health-care stock No. 2: Swinging for the fences
Geron (NASDAQ: GERN ) has a potential blockbuster on its hands; in a small clinical trial, some myelofibrosis patients taking its imetelstat went into complete remission.
Geron needs to run a larger clinical trial to confirm the results. Assuming imetelstat works as well in the larger trial and doesn't show any unmanageable side effects, imetelstat will be a blockbuster for sure.
Of course, that's easier said than done, but the potential reward looks like it's worth the risk. Geron has a market cap around $650 million while Incyte, which sells Jakafi -- the only approved drug to treat myelofibrosis -- is an $8 billing company. Based on the data so far, imetelstat appears to be a better drug than Jakafi, which treats the symptoms of myelofibrosis, but is far from a cure''.